AN2 Therapeutics, Inc.
About
Issuer
- Entity type
- Corporation
- Jurisdiction
- Delaware
- Sector
- Other
- Headquarters
- Menlo Park, CA
- Street
- 1300 El Camino Real, Suite 100
- Zip
- 94025
Offering
- Total offering
- $40M
- Amount sold
- $40M
- First sale
- Mar 10, 2026
- Min investment
- $0
- Securities
- Equity
- Federal exemption
- Rule 506(b)
- Investors so far
- 16
How this filing compares
Ranked #29 of 222 Other filings in March 2026 by offering amount.
Median Other filing in March 2026: $5.4M. This offering is 7.4× the median.
Other California filings this week: 137 Holdings ISI, LLC, Am Tech Fund I LP, ARTELO BIOSCIENCES, INC., Be Bold Beverage, Inc., Calia 9 LLC
Leadership
Eric Easom — Executive Officer (also: Director)
Joshua Eizen — Executive Officer
Lucy Day — Executive Officer
Sanjay Chanda — Executive Officer
Joseph S. Zakrzewski — Director
Kabeer Aziz — Director
Rob Readnour — Director
Gilbert Lynn Marks — Director
Stephanie Wong — Director
Patricia Martin — Director
Melvin Spigelman — Director
Margaret FitzPatrick — Director
Filing details
AN2 Therapeutics, Inc. filed a Form D with the SEC on March 25, 2026.